83Post-thrombotic syndrome (PTS) is the most common long-term complication of deep vein thrombosis (DVT) [1]. With a wide variety of presentations ranging from minor leg swelling to severe complications, such venous stasis ulcers, PTS can signifi cantly decrease quality of life [2]. Patients who have extensive DVT, recurrent ipsilateral thrombosis, a history of varicose veins, obesity, or residual thrombus are at an increased risk of developing PTS [1].The best therapeutic approach for the prevention of PTS remains a matter of debate [3,4]. Maintaining a therapeutic international normalized ratio (INR) with warfarin has been associated with lower chances of developing PTS. In patients with extensive DVT, randomized controlled trials have shown that the use of catheter directed lysis reduces the incidence of PTS [5,6]. Other research has suggested that extended treatment with low molecular weight heparin (LMWH) signifi cantly reduces the incidence of PTS and ulcers. In a systematic review of fi ve randomized trials in patients treated for DVT, LMWH (treatment duration for a minimum of three months) was associated with signifi cant increase in venous re-canalization (relative risk ratio 0.66; 95 % CI, 0.57 -0.77) and decrease in venous ulceration when compared with warfarin [7]. A recently published large randomized controlled trial showed no benefi t of graduated compression stockings for the prevention of PTS [8].Infl ammatory biomarkers such as interleukin-6, C-reactive protein (CRP), and intercellular adhesion molecule-1 may be used to predict the development of PTS [1]. In a recent cohort study, cHDL levels < 35 mg/dL and cLDL levels > than 180 mg/dL were risk factors for the development of recurrent thrombosis and PTS [9].In addition to a reduction in cholesterol and high-sensitivity CRP, current data suggests that statin therapy aff ects the coagulation cascade by inhibiting the activity of tissue factor and platelet activation by reducing the expression of circulating molecules, such as soluble CD40L or P-selectin [10]. In recent randomized controlled trials and metaanalysis, it has been suggested that statins reduce the incidence of fi rst occurrence venous thromboembolism [11,12]. Interestingly, statin therapy did not reduce the incidence of recurrent VTE in patients being treated for acute DVT or pulmonary embolism with oral anticoagulation [13].To date clinicians and researchers are still unclear as to whether or not statins can reduce the incidence of PTS. Recent data from animal models of VTE has suggested that statin therapy reduced the incidence of deep vein thrombosis induced vein wall scarring by 50 % [14]. In this issue of VASA-European Journal of Vascular Medicine, San Norberto and colleagues present the fi rst trial evaluating the use of statin therapy (rosuvastatin 10 mg (or 5 mg for patients > 70 years) for the prevention of PTS in patients treated for DVT [15]. In this trial, patients diagnosed with DVT were treated with three months of LMWH therapy and were randomized to receive rosuvastat...